JG
Therapeutic Areas
Virbac SA Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Feliscratch | Feline Behavior (Scratching) | Approved |
| Iverhart / Virbamec | Canine Heartworm & Intestinal Parasites | Approved |
| Cytopoint (lokivetmab) | Canine Atopic Dermatitis | Approved |
| Endovac-Porci | Porcine Respiratory Disease Complex | Approved |
| Hipraviar S.H.A.P. | Avian Influenza (Poultry) | Approved |
| Sealed Skin Support | Dermatological Support (Dog/Cat) | Approved |
| Osphos (clodronate) | Equine Lameness (Navicular Syndrome/Bone Spavin) | Approved |
| Next-generation Parasiticides | Parasite Control (Companion Animals) | R&D |
Leadership Team at Virbac SA
SH
Sébastien Huron
Chief Executive Officer (CEO)
ÉT
Éric Thébault
Deputy CEO
GD
Gilles de la Bassetière
Chief Financial Officer (CFO)
PD
Philippe Dulac
Executive Vice President, Research & Development
LL
Loïc Lemeunier
Executive Vice President, Commercial Operations - Companion Animals
FD
François de Ricolfis
Executive Vice President, Commercial Operations - Livestock
PD
Pierre-Richard Dick
Founder and Honorary President
ML
Michel Le Pen
Chairman of the Board of Directors